Innohep (tinzaparin) / LEO Pharma - LARVOL DELTA

An Experimental Study to Assess the Ecotoxicity of Warfarin and Tinzaparin on Meiobenthic Amphipods: Original Taxonomic Data from Saudi Arabia and Computational Modeling. (PubMed, Toxics) - "Ultimately, the similarity between the control amphipod replicates and those subjected to mixed anticoagulants (T1W1 and T2W2) suggests that warfarin may have reduced the toxicity of tinzaparin. Additionally, the computational study indicated that warfarin interacts with 4XNN and forms strong molecular interactions with several key residues, which contribute to the toxicokinetic characteristics observed in the empirical findings."

Journal

Comparison of Prophylactic and Therapeutic Doses of Anticoagulation for Acute Chest Syndrome in Sickle Cell Disease: The TASC Randomized Clinical Trial. (PubMed, Am J Respir Crit Care Med) - P3 | "In adult patients with ACS, a therapeutic anticoagulation shortened ACS duration and reduced opioids consumption compared with prophylactic doses, without increasing bleeding risk. Clinical trial registration available at www."

Clinical • Journal • Cardiovascular • Genetic Disorders • Hematological Disorders • Sickle Cell Disease • Thrombosis

Aticks Live: Effect of Tinzaparin on Inflammatory Biomarkers During the Acute Phase of Deep Vein Thrombosis (clinicaltrials.gov) - P=N/A | N=9 | Completed | Sponsor: Centre Hospitalier Universitaire, Amiens | Recruiting ➔ Completed

Trial completion • Cardiovascular • Hematological Disorders • Inflammation • Thrombosis • Venous Thromboembolism

The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity (clinicaltrials.gov) - P3 | N=8805 | Not yet recruiting | Sponsor: University of Calgary | Initiation date: Sep 2024 ➔ Apr 2025

Trial initiation date • Cardiovascular • Venous Thromboembolism

Efficacy and safety of extended duration postoperative thromboprophylaxis with low molecular weight heparin among subgroups of patients undergoing surgical resection of colorectal cancer: A post-hoc analysis of the PERIOP-01 trial. (PubMed, Eur J Surg Oncol) - "In the PERIOP-01 trial, extended thromboprophylaxis did not reduce the incidence of major VTE in any subgroups of patients. However, this strategy may be associated with an increased incidence of bleeding among patients with colon cancer, and perhaps among male and elderly patients."

Journal • Retrospective data • Cardiovascular • Colon Cancer • Colorectal Cancer • Hematological Disorders • Oncology • Solid Tumor • Venous Thromboembolism

Preferences for thromboprophylaxis in the intensive care unit: An international survey. (PubMed, Acta Anaesthesiol Scand) - "LMWH was the preferred agent for thromboprophylaxis in critically ill patients. There was considerable variation in the application of LMWH for prophylaxis, reflected by the use of different types, doses, and dosing strategies. Most physicians would be willing to participate in an RCT on thromboprophylaxis."

Clinical • Journal • Cardiovascular • Critical care • Venous Thromboembolism

PREPOSTEROUS: Pre- Vs Postoperative Thromboprophylaxis for Liver Resection (clinicaltrials.gov) - P4 | N=1012 | Recruiting | Sponsor: Helsinki University Central Hospital | Trial completion date: Mar 2025 ➔ Mar 2027 | Trial primary completion date: Feb 2025 ➔ Feb 2027

Trial completion date • Trial primary completion date • Cardiovascular • Hematological Disorders • Hepatology • Liver Cancer • Oncology • Pulmonary Embolism • Solid Tumor • Thrombosis

Treatment of radial artery occlusion after transradial coronary catheterization: a review of the literature and proposed treatment algorithm. (PubMed, Hellenic J Cardiol) - "There are only two randomized studies one with LMWH (tinzaparin) and one with apixaban. Therapeutic options include anticoagulation regimens and interventional techniques through the distal radial artery. Large, randomized, multicenter studies should be conducted to evaluate the efficacy of the available treatment methods and define a standardized treatment protocol for RAO."

Journal • Review

ACTIV-4: Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE (clinicaltrials.gov) - P4 | N=3591 | Completed | Sponsor: Matthew Neal MD | Active, not recruiting ➔ Completed | Trial completion date: Jun 2024 ➔ Jan 2024

Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease

Impact of Obesity on Anticoagulation Dosing and Clinical Outcomes in Pediatric Patients with Venous Thrombo-Embolism (ASH 2024) - "Anticoagulants used included LMWHs (enoxaparin [78.4%], dalteparin [n=1.9%], and tinzaparin [n=1.9%]) followed by UFH (17.4%) and were comparable between obese and non-obese children (p=0.797). Conclusion : In children receiving therapeutic anticoagulation for VTE, mostly treated with enoxaparin, obesity was associated with lower anticoagulation requirements. Further prospective work is urgently needed to explore alternate dosing regimens in obese pediatric patients, such as dose capping, reduced initial dosing, or the use of fat-free mass."

Clinical • Clinical data • Cardiovascular • Genetic Disorders • Heart Failure • Hematological Disorders • Obesity • Oncology • Pediatrics • Venous Thromboembolism

TiLLI: Thromboprophylaxis in Lower Limb Immobilisation (clinicaltrials.gov) - P3 | N=10044 | Recruiting | Sponsor: Queen Mary University of London | Not yet recruiting ➔ Recruiting

Cost effectiveness • Enrollment open • HEOR • Cardiovascular • Hematological Disorders • Thrombosis

Impact of Residual Vein Venous Thrombosis in Consecutive Patients with Cancer-Associated Thrombosis Treated with Tinzaparin-A Cohort Study. (PubMed, Cancers (Basel)) - " RVT is high in patients with CAT. The presence of RVT at 6 months was associated with an increased risk of recurrent VTE over 5 years."

Journal • Cardiovascular • Hematological Disorders • Oncology • Respiratory Diseases • Thrombosis • Venous Thromboembolism

Fondaparinux: A Cost-Saving Alternative to Low-Molecular-Weight Heparins for Venous Thromboembolic Event Prevention/Treatment and Acute Coronary Syndrome Treatment (ISPOR-EU 2024) - " Our model estimates per-patient costs and budget impact of fondaparinux versus LMWHs (enoxaparin, nadroparin, tinzaparin, parnaparin) for treatment and prevention of VTE and treatment of ACS. Avoidance of HIT-related costs results in cost-savings with fondaparinux compared with LMWH across all indications which can provide substantial budget savings. Further analysis will demonstrate potential cost savings with fondaparinux in other healthcare systems."

HEOR • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Respiratory Diseases

Risk of recurrent venous thromboembolism in patients with cancer: an individual patient data meta-analysis and development of a prediction model. (PubMed, Thromb Haemost) - "Results After excluding patients using vitamin K antagonists, the combined dataset comprised 2,245 patients with cancer and acute CAT who were treated with edoxaban (23%), rivaroxaban (9%), dalteparin (47%), or tinzaparin (20%). Conclusions The prediction model for recurrent CAT included five clinical predictors and has only modest discrimination. Prediction of recurrent CAT at the initiation of anticoagulation remains challenging."

Journal • Retrospective data • Breast Cancer • Cardiovascular • Hematological Disorders • Oncology • Solid Tumor • Venous Thromboembolism

Effects of tinzaparin on the presence of residual thrombus in patients with cancer-associated thrombosis (ERS 2024) - "One-third of cancer-associated VTE patients have residual thrombosis, with identified variables associated with residual thrombosis."

Clinical • Cardiovascular • Hematological Disorders • Oncology • Respiratory Diseases • Thrombosis • Venous Thromboembolism

TiLLI: Thromboprophylaxis in Lower Limb Immobilisation (clinicaltrials.gov) - P3 | N=10044 | Not yet recruiting | Sponsor: Queen Mary University of London | Trial completion date: Feb 2028 ➔ Aug 2028 | Initiation date: May 2024 ➔ Sep 2024 | Trial primary completion date: Feb 2028 ➔ Aug 2028

Cost effectiveness • HEOR • Trial completion date • Trial initiation date • Trial primary completion date • Cardiovascular • Hematological Disorders • Thrombosis

The effect of tinzaparin on biomarkers in FIGO stages III-IV ovarian cancer patients undergoing neoadjuvant chemotherapy - the TABANETOC trial: study protocol for a randomized clinical multicenter trial. (PubMed, Acta Oncol) - "This study will make an important contribution to the knowledge of the anti-neoplastic effects of tinzaparin in EOC patients and may thus guide the planning of a future study on the impact of tinzaparin on survival in EOC."

Biomarker • Clinical • Clinical protocol • Journal • Gynecology • Obstetrics • Oncology • Ovarian Cancer • Solid Tumor

Tinzaparin, an alternative to subcutaneous unfractionated heparin, in patients with severe and end-stage renal impairment: a retrospective observational single-center study. (PubMed, J Thromb Haemost) - "Tinzaparin PK parameters and profiles were not affected by renal impairment. This suggests that tinzaparin, at therapeutic or prophylactic dose, could be an alternative to unfractionated heparin in hospitalized patients with severe renal impairment."

Journal • Retrospective data • Hematological Disorders • Nephrology • Renal Disease

Molecular dissection of cobra venom highlights heparinoids as an antidote for spitting cobra envenoming. (PubMed, Sci Transl Med) - "Heparinoids prevented venom cytotoxicity through binding to three-finger cytotoxins, and the US Food and Drug Administration-approved heparinoid tinzaparin was found to reduce tissue damage in mice when given via a medically relevant route and dose. Overall, our systematic molecular dissection of cobra venom cytotoxicity provides insight into how we can better treat cobra snakebite envenoming."

Journal • EXT1

Carcinoid Heart Disease and a Complicated Course of Progressive Gastroenteropancreatic Neuroendocrine Neoplasia: A Case Report. (PubMed, Case Rep Oncol) - "He was on treatment with subcutaneous lanreotide 120 mg twice weekly prior to admission...The patient was started on IV furosemide 40 mg twice daily, SC octreotide 100 μg three times daily, and therapeutic tinzaparin...This case report highlights the importance of regular echocardiogram and cardiovascular checkups in patients with carcinoid tumours and liver metastases. A multidisciplinary approach involving medical oncologists, cardiothoracic surgeons, and cardiologists is vital in ensuring early treatment and preventing late-stage complications of carcinoid heart disease."

Journal • Carcinoid Syndrome • Carcinoid Tumor • Cardiovascular • Congestive Heart Failure • Endocrine Cancer • Fibrosis • Heart Failure • Hepatology • Neuroendocrine Tumor • Oncology • Pain • Pancreatic Cancer • Pulmonary Embolism • Respiratory Diseases • Solid Tumor

Hemodialysis patients have signs of a chronic thrombotic burden. (PubMed, BMC Nephrol) - "D-dimer levels were elevated in a high proportion predialysis and during HD and related to the IDWG and the UF-rate. Awareness of D-dimer levels and future studies will help clarify if optimization of those variables, besides anticoagulation and biocompatibility measures, will eradicate the repeated subclinical thromboembolic events related to each HD; one reason that may explain organ damage and shortened life span of these patients."

Journal • Observational data • Cardiovascular • Hematological Disorders • Renal Disease • Thrombosis

The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity (clinicaltrials.gov) - P3 | N=8805 | Not yet recruiting | Sponsor: University of Calgary

New P3 trial • Cardiovascular • Venous Thromboembolism

PRIMARY AMBULATORY THROMBOPROPHYLAXIS (PATP) IN PATIENTS WITH LUNG CANCER UNDERGOING SYSTEMIC THERAPY: UPDATED ANALYSIS OF RANDOMIZED STUDIES (EHA 2024) - "5,526 patients with LC from five RCTs and subgroups of another six RCTs were eligible. Bemiparin, certoparin,dalteparin, nadroparin, semuloparin, tinzaparin, enoxaparin, rivaroxaban and apixaban were used. The durationof the anticoagulation ranged from 3 to 6 months."

Clinical • Cardiovascular • Hematological Disorders • Lung Cancer • Oncology • Solid Tumor • Venous Thromboembolism

INCIDENCE AND PREDISPOSING FACTORS OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE NON-PROMYELOCYTIC MYELOID LEUKEMIA: EXPERIENCE FROM TWO CENTERS (EHA 2024) - "5mg qdLeukostasis,immobility,varicose oflowerextremities4M39YesPE, inferiorvena cavaand iliacveinthrombosisDiagnosisEnoxaparin6000 bid5F65YesLower limbSVTDiagnosisTinzaparin10000 qdActive ovariancancer6M77NoLower limbSVTDiagnosisFondaparinux2. Venous thromboembolic events in non-PML AML patients are not insignificant andmay complicate the diagnosis and/or treatment period. Risk category and ICT are associated with the risk ofthrombosis possibly through an interaction of hemostasis with pathogenesis of the disease, patients'characteristics and treatment. Studies focusing on the underlying mechanisms of thrombosis in AML patientsare of outmost interest."

Clinical • Acute Myelogenous Leukemia • Cardiovascular • Hematological Disorders • Hematological Malignancies • Infectious Disease • Ischemic stroke • Leukemia • Myocardial Infarction • Novel Coronavirus Disease • Oncology • Ovarian Cancer • Solid Tumor • Thrombocytopenia • Thrombosis • Venous Thromboembolism

Preferences of thromboprophylaxis in the intensive care unit: an international survey (ISTH 2024) - "Seventy-five percent of respondents indicated that they used enoxaparin 40mg (4000 IU), dalteparin 5000 IU or tinzaparin 4500 IU once daily, whereas 25% reported the use of 16 other LMWH type and dose combinations. A total of 715 respondents from 170 ICUs in 23 countries contributed information, with a mean response rate of 36%. In most ICUs both pharmacological (n=166, 98%) and mechanical thromboprophylaxis (n = 143, 86%) were applied. A total of 36 pharmacological thromboprophylaxis regimens were reported."

Cardiovascular • Critical care • Venous Thromboembolism